Home » News & Trends » Uractiv portfolio acquired by Sun Pharma from Fiterman Pharma in Romania

News & Trends

Uractiv portfolio acquired by Sun Pharma from Fiterman Pharma in Romania

Uractiv portfolio

Sun Pharma acquires Uractiv portfolio from Fiterman Pharma

Sun Pharmaceutical, an Indian multinational pharma company, announced on Friday that one of its Romanian subsidiaries, S.C. Terapia S.A, had acquired the Uractiv portfolio from Fiterman Pharma. Uractiv’s product line includes food supplements, such as minerals, vitamins, and adjuvants, as well as cosmetics and medical equipment for urinary tract health. 
Annualized revenues for the portfolio, which includes 12 stock keeping units (SKUs), are around $8.7 million. Adults and children will benefit from the products. 
Sun Pharma’s Aalok Shanghvi, EVP and Head-Generic R&D, Generic Global BD and Emerging Regions, said, “This acquisition is in keeping with our plan to significantly extend our non-prescription product basket in Romania and neighbouring markets.”

Uractiv portfolio

Terapia leads the generics and over-the-counter (OTC) market in Romania, where we have a significant presence. He went on to say, “We’ll use our tremendous marketing and distribution capabilities to assist these firms grow even more.” 
The deal is contingent to usual closing conditions and regulatory clearances. The transaction’s financial terms are kept under wraps. 
According to AWACS, a pharmaceutical industry research firm, Sun Pharma is India’s largest pharmaceutical company, with over 8% market share in the domestic market. Sun Pharma India specializes in technically complicated medications with a broad therapeutic range, and it owns over 30 of India’s top 300 pharmaceutical brands. Neuro-Psychiatry (17%), Gastroenterology (12%), Anti-Infectives (10%), Diabetology (9%), and Pain/Analgesics (7%), among others, are the major therapeutic sectors that contribute considerably to the company’s revenue and market share.